GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (TSXV:RKV) » Definitions » Current Accrued Expense

Rakovina Therapeutics (TSXV:RKV) Current Accrued Expense : C$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Rakovina Therapeutics Current Accrued Expense?

Rakovina Therapeutics's Current Accrued Expense for the quarter that ended in Dec. 2024 was C$0.00 Mil.


Rakovina Therapeutics Current Accrued Expense Historical Data

The historical data trend for Rakovina Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rakovina Therapeutics Current Accrued Expense Chart

Rakovina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Current Accrued Expense
- - - -

Rakovina Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Rakovina Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Rakovina Therapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Rakovina Therapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Rakovina Therapeutics Business Description

Traded in Other Exchanges
Address
105 1008 Beach Avenue, Vancouver, BC, CAN, V6E 1T7
Rakovina Therapeutics Inc is a biopharmaceutical research company focused on the development of cancer treatments. Its work is based on technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, it can review and optimize drug candidates at a much greater pace than ever before. The company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.
Executives
Jeffrey Bacha Senior Officer
Alfredo De Lucrezia Director, Senior Officer
Michael Liggett Director
Mads Daugaard Senior Officer
David Hyman Senior Officer
John Michael Langlands Senior Officer

Rakovina Therapeutics Headlines

No Headlines